Tay-Sachs Disease — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Long-term follow-up of a Tay-Sachs disease patient with cherry-red spot.
Tsutsumi Noriko et al. — American journal of ophthalmology case reports (1 June 2026)
https://pubmed.ncbi.nlm.nih.gov/41783478/
- 2.
Generation and characterization of induced pluripotent stem cell (iPSC) lines from patients affected with Tay-Sachs and Sandhoff disease.
Jovanovic Vukasin M et al. — Stem cell research (1 April 2026)
https://pubmed.ncbi.nlm.nih.gov/41795546/
- 3.
Tay-Sachs disease models: From cellular and animal models to treatment perspectives.
Suarez Diego A et al. — Molecular genetics and metabolism (18 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41880697/
- 4.
Human Neuraminidase 3 reduces the severity of Tay-Sachs disease symptoms in a mouse model.
Basırlı Hande et al. — Neurochemistry international (10 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41819452/
- 5.
B4Galnt1 Deficiency Reverses Severe Neurological Symptoms in a Mouse Model of Tay-Sachs Disease.
Yanbul Selman et al. — Neuromolecular medicine (9 March 2026)
https://pubmed.ncbi.nlm.nih.gov/41803330/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease, GM1 Gangliosidosis or GM2 Gangliosidosis
Recruiting — Phase 3 — Azafaros A.G.
https://clinicaltrials.gov/study/NCT07054515
- 2.
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of Niemann-Pick Type C Disease (NPC)
Recruiting — Phase 3 — Azafaros A.G.
https://clinicaltrials.gov/study/NCT07082725
- 3.
A Study to Evaluate the Safety and Efficacy of Oral Nizubaglustat (AZ-3102) in Late-infantile and Juvenile Forms of GM1 Gangliosidosis or GM2 Gangliosidosis
Recruiting — Phase 3 — Azafaros A.G.
https://clinicaltrials.gov/study/NCT07082543
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Tay-Sachs Disease
Tay-Sachs Disease is a rare inherited lysosomal storage disorder caused by mutations in the HEXA gene, resulting in the toxic accumulation of gangliosides in nerve cells. The infantile form is typically fatal by age 5; late-onset forms present in adolescence or adulthood. Carrier screening in at-risk populations (Ashkenazi Jewish, French-Canadian) has dramatically reduced incidence.
Most Recent Research
PURPOSE: To describe the clinical progression and ophthalmic findings in a Japanese boy with Tay-Sachs disease at ages 5 and 8 months. RESULTS: The patient was born at 38 weeks of gestation and developed normally until motor skill delays were identified at age 1 year and 1 month. At that time, brain magnetic resonance imaging revealed diffuse T2 hyperintensity in the bilateral basal ganglia. At age 1 year and 6 months, he was able to fix and follow objects, and the optic discs appeared normal, but bilateral cherry-red spots were observed in the maculae. Based on these findings, together with hypersensitivity to sound and markedly reduced β-hexosaminidase A activity, Tay-Sachs disease was biochemically diagnosed. By age 2 years and 1 month, the patient had lost the ability to fixate on and follow objects. Fundoscopy at age 4 years and 4 months revealed optic atrophy and reduced cherry-red spots, electroretinography (ERG) at age 4 years and 9 months showed a complete loss of retinal responses, and optical coherence tomography at age 5 years and 3 months demonstrated retinal thinning. Long-term observation revealed progressive degeneration, consistent with previous reports. Lipid deposition in all retinal layers was considered to contribute to retinal atrophy. CONCLUSIONS: This report highlights progressive retinal degeneration with optic atrophy, retinal thinning, and reduction in cherry-red spots. The flat ERG waveform in this patient suggests more advanced retinal involvement than in previous reports and provides insights into the ocular manifestations of Tay-Sachs disease.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.